| Chemical Properties | Back Directory | [Boiling point ]
435.4±40.0 °C(Predicted) | [density ]
1.246±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 2 mg/ml | [form ]
A crystalline solid | [pka]
1?+-.0.48(Predicted) |
| Hazard Information | Back Directory | [Description]
PAQ is a neuroprotective agent. It protects dopaminergic neurons from cell death without inhibiting glial cell proliferation in a rat midbrain culture model of Parkinson’s disease when used at a concentration of 10 μM. PAQ (25 or 50 mg/kg, twice per day) prevents loss of dopaminergic neurons in the substantia nigra in a mouse model of Parkinson’s disease induced by MPTP. | [Uses]
PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells[1]. | [in vivo]
PAQ (25-50 mg/kg, p.o., 11 days) exhibits a neuroprotective effect on SN DA neurons in C57BL/6 mice model of PD[1]. | Animal Model: | Neurotoxin MPTP (HY-15608) induced dopamine depletion in Parkinson disease in C57BL/6 mice[1] | | Dosage: | 25-50 mg/kg | | Administration: | p.o. for 11 days | | Result: | Reduced levels of striatal DA and DOPAC+HVA/DA ratios. Maintained dendritic network in midbrain tissue sections in TH+ neurons. |
| [References]
[1] Le Douaron G, et al., New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models. J Med Chem. 2016 Jul 14;59(13):6169-86. DOI:10.1021/acs.jmedchem.6b00297 |
|
|